<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of refractory pemphigus vulgaris and pemphigus foliaceus</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of refractory pemphigus vulgaris and pemphigus foliaceus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of refractory pemphigus vulgaris and pemphigus foliaceus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Hertl, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rüdiger Eming, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John J Zone, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H13593182"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pemphigus vulgaris and pemphigus foliaceus are autoimmune blistering diseases that may result in significant morbidity and death. Treatment with either <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> and a systemic glucocorticoid or with a systemic glucocorticoid with or without an adjuvant immunosuppressive medication (eg, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>) is the mainstay of initial treatment. (See  <a class="medical medical_review" href="/z/d/html/15303.html" rel="external">"Initial management of pemphigus vulgaris and pemphigus foliaceus"</a>.)</p><p>Patients who do not achieve disease control with the selected initial therapy generally first proceed to escalation of initial treatment with systemic glucocorticoids, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, and/or adjuvant immunosuppressants (<a class="graphic graphic_algorithm graphicRef134326" href="/z/d/graphic/134326.html" rel="external">algorithm 1</a>). Patients for whom this is insufficient may benefit from other interventions, such as intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG), immunoadsorption, plasmapheresis, and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>. (See  <a class="medical medical_review" href="/z/d/html/15303.html" rel="external">"Initial management of pemphigus vulgaris and pemphigus foliaceus", section on 'Assessing the response to therapy'</a> and  <a class="medical medical_review" href="/z/d/html/15303.html" rel="external">"Initial management of pemphigus vulgaris and pemphigus foliaceus", section on 'Failure to achieve disease control'</a>.)</p><p>Therapeutic options for pemphigus vulgaris or pemphigus foliaceus refractory to escalation of initial therapy will be reviewed here. The initial management of pemphigus vulgaris and pemphigus foliaceus, escalation of treatment after failure to achieve disease control with initial therapy, and the management of relapses after initial disease control are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15303.html" rel="external">"Initial management of pemphigus vulgaris and pemphigus foliaceus", section on 'Initial therapy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15303.html" rel="external">"Initial management of pemphigus vulgaris and pemphigus foliaceus", section on 'Failure to achieve disease control'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15303.html" rel="external">"Initial management of pemphigus vulgaris and pemphigus foliaceus", section on 'Management of relapses'</a>.)</p><p></p><p>Paraneoplastic pemphigus is also reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15305.html" rel="external">"Paraneoplastic pemphigus"</a>.)</p><p></p><p class="headingAnchor" id="H1593050620"><span class="h1">APPROACH TO THERAPY</span><span class="headingEndMark"> — </span>The use of therapies generally reserved for refractory pemphigus (intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> [IVIG], immunoadsorption, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and plasmapheresis) involves the identification of appropriate treatment candidates and treatment selection. (See <a class="local">'Candidates'</a> below and <a class="local">'Treatment options'</a> below and <a class="local">'Treatment selection'</a> below.)</p><p>Whenever possible, the therapies utilized for refractory pemphigus should be administered by clinicians experienced in the use and adverse effects of these treatments. Referral to specialized treatment centers can be useful for additional access to treatments.</p><p class="headingAnchor" id="H958375592"><span class="h2">Candidates</span><span class="headingEndMark"> — </span>Patients who fail to achieve disease control despite escalation of initial treatment are candidates for refractory disease therapies. Escalation of treatment typically consists of increasing the dose of the systemic glucocorticoid, adding <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (if not already received), and/or adding or adjusting conventional immunosuppressive therapy (<a class="graphic graphic_algorithm graphicRef134326" href="/z/d/graphic/134326.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/15303.html" rel="external">"Initial management of pemphigus vulgaris and pemphigus foliaceus"</a>.)</p><p>Patients with contraindications to initial therapies or who are unable to tolerate initial treatments may also benefit from treatments used for refractory disease.</p><p>Occasionally, refractory disease therapies are used prior to the failure of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> for patients presenting with severe disease. (See <a class="local">'Use prior to failure of rituximab'</a> below.)</p><p class="headingAnchor" id="H3040154315"><span class="h2">Treatment options</span><span class="headingEndMark"> — </span>The major therapeutic options for disease refractory to escalation of treatment include interventions that directly target the antibody-mediated pathogenesis of pemphigus (<a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>, immunoadsorption, and plasmapheresis) and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, a drug that may be used as an alternative adjuvant immunosuppressant. These therapies are typically added to a baseline immunosuppressive regimen that consists of systemic glucocorticoids with or without an adjuvant conventional immunosuppressant. (See  <a class="medical medical_review" href="/z/d/html/15303.html" rel="external">"Initial management of pemphigus vulgaris and pemphigus foliaceus", section on 'Adjuvant conventional immunosuppressive therapies'</a>.)</p><p>The availability of higher-quality data to support the efficacy of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> in pemphigus; high cost and technical requirements for the administration of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>, immunoadsorption, and plasmapheresis; and the unfavorable adverse effect profile of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> (eg, sterility, cytopenia, hemorrhagic cystitis, bladder cancer) contribute to the preferred use of these agents for refractory pemphigus rather than for new-onset disease. (See  <a class="medical medical_review" href="/z/d/html/15303.html" rel="external">"Initial management of pemphigus vulgaris and pemphigus foliaceus", section on 'Rituximab and systemic glucocorticoids'</a>.)</p><p class="headingAnchor" id="H3379265412"><span class="h2">Treatment selection</span><span class="headingEndMark"> — </span>The paucity of high-quality studies on the treatment of refractory pemphigus with <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>, immunoadsorption, plasmapheresis, or <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> impedes both conclusions on the relative efficacies of these interventions and the formation of definitive guidelines on the best approach to the treatment of refractory disease. Thus, therapeutic choice remains heavily influenced by consideration of patient tolerance (including contraindications) for specific treatments and treatment availability.</p><p class="headingAnchor" id="H4063879214"><span class="h3">Patient-specific considerations</span><span class="headingEndMark"> — </span>Examples of clinical scenarios that have influenced the choice of therapy for our patients include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Desire to preserve childbearing potential</strong> – Preference to avoid <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> in a patient of childbearing potential due to the risk of cyclophosphamide-induced premature gonadal failure</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presence of severe heart disease</strong> – Preference to avoid extracorporeal therapies such as immunoadsorption and plasmapheresis in older patients with severe heart disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Need for rapid-acting therapy</strong> – Preference for use of a rapid-acting therapy (eg, intravenous immunoglobulins, immunoadsorption, plasmapheresis) in patients with severe manifestations of the disease</p><p></p><p class="headingAnchor" id="H1254930285"><span class="h3">Treatment availability</span><span class="headingEndMark"> — </span>Treatment availability is a major factor in treatment selection that is based on both the ability to obtain a treatment and access to appropriate equipment and expertise to administer it safely. For example, although the use of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> for refractory pemphigus has decreased in clinical settings where patients have access to other, less toxic treatment options, the relatively higher cost and more limited access to <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>, immunoadsorption, and plasmapheresis has contributed to the continued use of cyclophosphamide in certain clinical settings.</p><p class="headingAnchor" id="H2329168847"><span class="h2">Use prior to failure of rituximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> has also been combined with <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>, immunoadsorption, or plasmapheresis <strong>prior to </strong>assessing the response to rituximab, with the intent of taking advantage of the fast onset of action of these therapies [<a href="#rid1">1-5</a>]. We have used combination therapy with immunoadsorption and rituximab for patients with severe, refractory disease (extensive involvement or involvement of mucosal sites that may result in significant morbidity [conjunctiva, pharynx, larynx, or esophagus]).</p><p>Although rapid and long-lasting remissions have been reported in uncontrolled studies of patients with refractory pemphigus who were treated with combination therapy [<a href="#rid1">1-5</a>], the efficacy of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> given with and without these therapies has not been directly compared. Additional studies are necessary to confirm whether this approach is beneficial. The efficacy of efgartigimod, which may be another fast-acting therapy, is under investigation. (See <a class="local">'Other therapies and regimens for pemphigus'</a> below.)</p><p class="headingAnchor" id="H13593224"><span class="h1">INTRAVENOUS IMMUNE GLOBULIN</span><span class="headingEndMark"> — </span>Intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) appears to be effective for refractory pemphigus. However, the mechanism through which IVIG improves pemphigus is not fully understood. Some authors have proposed that the infusion of IVIG may contribute to a reduction in circulating pemphigus autoantibodies by stimulating an increase in catabolism of immunoglobulins [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H341812371"><span class="h2">Administration and efficacy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> therapy for adults is typically given as 2 g/kg given over two to five consecutive days every four weeks [<a href="#rid7">7,8</a>]. (See  <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">"Overview of intravenous immune globulin (IVIG) therapy"</a>.)</p><p>The highest-quality evidence for a beneficial therapeutic effect of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> in pemphigus is provided by an 85-day, multicenter, randomized trial in 61 adults with glucocorticoid-resistant pemphigus (defined as a failure to respond to the equivalent of 20 mg per day or more of <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a>) [<a href="#rid9">9</a>]. Patients in the trial were treated with 400 mg/kg of IVIG per day for five days, 200 mg/kg of IVIG per day for five days, or a placebo infusion for five days. The primary endpoint in the trial was the duration of time that patients could be maintained on the treatment protocol before symptoms required additional treatment (ie, time to escape protocol).</p><p>The trial found that the time to escape protocol was significantly longer for patients in the 400 mg <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> group compared with the patients in the placebo group [<a href="#rid9">9</a>], supporting a beneficial effect of the 400 mg dose of IVIG. The difference in the time to escape protocol for the 200 mg IVIG group and the placebo group was not statistically significant. Furthermore, a significant decrease in a pemphigus activity score was detected at all study observation points for patients in the 400 mg IVIG group and at all study observation points after day 15 in the 200 mg IVIG group. The pemphigus activity score did not decrease significantly at any time point in the placebo group.</p><p>Several uncontrolled studies and case series provide additional support for the use of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> for refractory pemphigus [<a href="#rid6">6,10-14</a>]. In most of the series, patients received IVIG at a dose of 2 g/kg/cycle consisting of two to four consecutive treatment days, and IVIG cycles were repeated in four- to six-week intervals. In some studies, clinical improvement following IVIG has been found to correlate with decreasing titers of desmoglein-specific immunoglobulin G (IgG) autoantibodies [<a href="#rid6">6,14</a>]. Additionally, a glucocorticoid-sparing effect of adjuvant IVIG was suggested by a small, retrospective study that found significant reductions in glucocorticoid requirements following treatment with adjuvant IVIG [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H341812364"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>In general, <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> therapy is well tolerated. Adverse events are usually mild to moderate (eg, headache, back pain, increased blood pressure, abdominal discomfort) [<a href="#rid9">9</a>]. Aseptic meningitis is a serious side effect of IVIG therapy that requires immediate termination of treatment. Mostly, patients have a history of migraine or are prone to headache in general. Anaphylaxis is a potential risk of IVIG treatment in patients with a lack of immunoglobulin A (IgA). Therefore, absence of serum IgA (not deficiency) needs to be excluded prior to IVIG therapy. (See  <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects"</a>.)</p><p class="headingAnchor" id="H36962160"><span class="h1">IMMUNOADSORPTION</span><span class="headingEndMark"> — </span>Immunoadsorption is a therapeutic option for pemphigus that functions through the removal of circulating autoantibodies. In contrast to plasmapheresis, which nonselectively removes plasma proteins from circulation, immunoadsorption removes circulating IgG with a very high specificity [<a href="#rid15">15</a>]. (See <a class="local">'Plasmapheresis'</a> below.)</p><p>The high cost and potential side effects (thrombophlebitis, venous thrombosis, bacterial infections, sepsis) of immunoadsorption limit use of this therapy. In addition, immunoadsorption for pemphigus is not available in some countries, including the United States. In light of the phase 2 data with efgartigimod, an antagonist of the neonatal Fc receptor that leads to a rapid turnover of immunoglobulins (including IgG autoantibodies), less invasive regimens leading to degradation of pathogenic autoantibodies may eventually replace more invasive procedures, such as immunoadsorption and plasmapheresis. (See <a class="local">'Other therapies and regimens for pemphigus'</a> below.)</p><p class="headingAnchor" id="H36965124"><span class="h2">Administration and efficacy</span><span class="headingEndMark"> — </span>Immunoadsorption is administered as a minimum of two cycles of immunoadsorption performed over three to four consecutive days, with the cycles separated by four weeks [<a href="#rid7">7</a>].</p><p>Several apheresis systems for immunoadsorption have been successfully applied in pemphigus. The most effective columns include regenerative adsorber such as protein A or synthetic ligands that have a high affinity to the Fc portion of human IgG [<a href="#rid16">16-19</a>].</p><p>The efficacy of immunoadsorption for removing pemphigus autoantibodies is influenced by the adsorber utilized and treatment protocol. In one study in which protein A adsorber was utilized, levels of antibodies against desmogleins 1 and 3 were reduced by an average of 76 percent one month after the start of immunoadsorption treatment [<a href="#rid16">16</a>]. Immunoadsorption is typically administered as an adjuvant to immunosuppressive therapies in short three- to four-day cycles that are repeated every three to four weeks [<a href="#rid16">16-18,20</a>].</p><p>Data on the clinical efficacy of immunoadsorption in pemphigus are primarily limited to small, uncontrolled studies and case series [<a href="#rid16">16-19</a>]. The initial response to treatment can be rapid, occurring within a few weeks. Long-term improvement after immunoadsorption has been reported in several case series [<a href="#rid16">16,18</a>]. In our experience, patients with extensive skin involvement seem to benefit most from the addition of adjuvant immunoabsorption to immunosuppressive therapy.</p><p class="headingAnchor" id="H36964247"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>Most patients appear to tolerate immunoadsorption well. Infrequently reported adverse effects that may be directly related to immunoadsorption therapy include thrombophlebitis, venous thrombosis, bacterial infections, and sepsis from a central catheter [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H4171122147"><span class="h1">CYCLOPHOSPHAMIDE</span><span class="headingEndMark"> — </span>Treatment regimens that include <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> may be useful for inducing remission in pemphigus and reducing dependence on systemic glucocorticoids [<a href="#rid21">21</a>]. The beneficial effect of cyclophosphamide in pemphigus is likely related to the drug's suppressive effect on B lymphocytes and the ensuing reduction in autoantibody production [<a href="#rid22">22</a>]. The adverse effect profile of cyclophosphamide contributes to the restriction of its use primarily for refractory disease [<a href="#rid23">23</a>]. (See <a class="local">'Adverse effects'</a> below.)</p><p class="headingAnchor" id="H2022039234"><span class="h2">Administration and efficacy</span><span class="headingEndMark"> — </span>Similar to <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> and <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> is usually prescribed as an adjuvant to systemic glucocorticoid therapy.</p><p>Several series have documented high rates of successful treatment of pemphigus with an intravenous pulsed regimen of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> (monthly intravenous infusion of dexamethasone [100 mg for three days] and cyclophosphamide [500 mg for one day] plus daily 50 mg doses of oral cyclophosphamide in between pulsed therapy) [<a href="#rid24">24-26</a>]. However, less consistently favorable results with this regimen have also been reported [<a href="#rid27">27</a>]. Intravenous cyclophosphamide has also been utilized with other regimens (eg, 0.5 to 1 g/m<sup>2</sup> body surface area per month for three to six months) [<a href="#rid28">28,29</a>].</p><p>A glucocorticoid-sparing effect of adjuvant <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> given in a different regimen was demonstrated in a one-year, randomized trial (n = 120) that compared the efficacy of four different regimens for newly diagnosed pemphigus [<a href="#rid21">21</a>]. Although the rate of clinical response was similar among patients treated with both <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> (2 mg/kg per day followed by a taper) and cyclophosphamide (one 1000 mg intravenous dose per month for six months and every other month thereafter) and patients treated with prednisolone alone (73 and 77 percent, respectively), the cyclophosphamide group had a lower mean total dose of prednisolone (8276 versus 11,631 mg). Further, the glucocorticoid-sparing effects of cyclophosphamide were similar to the glucocorticoid-sparing effects of adjuvant <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> and <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil.</p><p>The effects of treatment regimens with <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> specifically on patients with refractory pemphigus have been evaluated in uncontrolled studies that have demonstrated favorable results in some patients [<a href="#rid23">23,30</a>]. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective, uncontrolled study, 23 patients with pemphigus (20 with pemphigus vulgaris and 3 with pemphigus foliaceus) who had disease refractory to <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> plus <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> and/or <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, who could not tolerate other therapies, or who had rapidly progressive, extensive disease were treated with oral <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> (2 to 2.5 mg/kg of ideal body weight per day) and prednisone (1 mg/kg of ideal body weight per day followed by a taper after two to three months) [<a href="#rid30">30</a>]. Of note, nine patients with severe disease also received plasma exchange during the first two weeks of treatment.</p><p></p><p class="bulletIndent1">Complete remission (defined as the absence of lesions for at least four weeks while on treatment with <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> and less than 0.15 mg/kg per day of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>) was achieved by 17 of 20 patients with pemphigus vulgaris (85 percent) and two of three patients with pemphigus foliaceus. Three patients with pemphigus vulgaris failed to respond to treatment, and one patient with pemphigus foliaceus had a partial response. The median time to remission was 8.5 months for patients who did not receive plasma exchange and 8 months for those who received the additional treatment. Six of 12 patients who achieved complete remission and subsequently discontinued treatment with cyclophosphamide relapsed within a median time of six months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study, 21 patients with pemphigus refractory to <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> plus <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (18 with pemphigus vulgaris, 2 with pemphigus foliaceus, and 1 with paraneoplastic pemphigus) were treated with 4 to 22 pulses of intravenous <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> (1 g per day for three consecutive days) together with 500 mg of intravenous <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> on the second day of treatment [<a href="#rid23">23</a>]. Between the monthly pulse treatments, patients were given oral cyclophosphamide (50 mg per day) and prednisolone. Continuation of adjuvant therapy with other immunosuppressives (<a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil and/or methotrexate) was allowed.</p><p></p><p class="bulletIndent1">The study found a statistically significant reduction in skin and oral disease scores after treatment. Seven patients (33 percent) achieved an excellent response (defined as quiescent disease), and a lesser degree of response was observed in an additional 13 patients. The median number of pulses given to patients who achieved an excellent response was 12 (range 6 to 19). In addition, four patients with excellent responses achieved clinical remission (defined as complete resolution of blisters and erosions for at least six months) that lasted for six months to six years. One of these patients was able to completely discontinue treatment, while the other three remained on <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil and low-dose <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a>.</p><p></p><p>A few case reports have documented the successful use of immunoablative high-dose <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> for severe, refractory pemphigus [<a href="#rid31">31,32</a>]. However, treatment is not uniformly effective, and a disease flare within weeks after treatment has been reported in a patient [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H3264474540"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>Adverse effects of this cytotoxic drug include myelosuppression, systemic infections, urine bladder toxicity, increased malignancies, and premature gonadal failure. Patients receiving <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> should be closely monitored for adverse effects of treatment. (See  <a class="medical medical_review" href="/z/d/html/7987.html" rel="external">"General toxicity of cyclophosphamide in rheumatic diseases"</a> and  <a class="medical medical_review" href="/z/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases", section on 'Monitoring of oral CYC dosing'</a>.)</p><p class="headingAnchor" id="H1037321153"><span class="h1">PLASMAPHERESIS</span><span class="headingEndMark"> — </span>Compared with immunoadsorption, which specifically removes circulating IgG, plasmapheresis (also known as plasma exchange) nonselectively removes plasma proteins from circulation. Plasmapheresis is a more widely available therapy.</p><p>Given limited efficacy in removing pathogenic autoantibodies and the lack of high-quality trials confirming efficacy of plasmapheresis, plasmapheresis is no longer a mainstay in the treatment of refractory pemphigus. (See  <a class="medical medical_review" href="/z/d/html/7941.html" rel="external">"Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology"</a>.)</p><p>Although small, uncontrolled studies and case reports have associated improvement in pemphigus with plasmapheresis [<a href="#rid33">33-39</a>], a randomized trial of 40 patients in which treatment with <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> alone was compared with prednisolone plus plasmapheresis found no significant difference in efficacy [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H36963996"><span class="h1">OTHER THERAPIES AND REGIMENS FOR PEMPHIGUS</span><span class="headingEndMark"> — </span>In addition to the major therapeutic options for the initial treatment of pemphigus vulgaris and pemphigus foliaceus and the management of refractory disease, multiple other interventions have been reported to be of benefit in small numbers of patients. Additional studies are necessary to confirm efficacy of these therapies:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intralesional </strong><strong>rituximab</strong> – Limited data suggest that intralesional injection of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> may be an effective treatment modality for oral pemphigus. In an open study, all three patients given intralesional rituximab (5 mg/cm<sup>2</sup> on days 1 and 15) for refractory oral pemphigus vulgaris had marked improvement [<a href="#rid41">41</a>]. One patient achieved clinical remission of oral lesions at week 12, and the remaining two patients achieved clinical remission at week 16. Adverse effects were limited to pain from injection in one patient. Of note, marked reductions in peripheral blood CD19<sup>+</sup> B cell counts were noted in all patients two weeks after the initial treatment session. Patients were followed for up to six months; one patient relapsed five months after the start of therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low-dose </strong><strong>rituximab</strong> – <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> administered in a lower dose than described above may be effective for pemphigus [<a href="#rid42">42,43</a>], though further study is necessary to clarify whether long-term outcomes are less favorable when compared with outcomes from higher-dose regimens [<a href="#rid42">42-44</a>]. Lower-dose regimens (eg, two 500 mg doses of rituximab separated by two weeks) may be associated with reduced duration of remission.</p><p></p><p class="bulletIndent1">The comparative efficacy of low-dose <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (two 500 mg doses of rituximab separated by two weeks) and standard rheumatologic dosing of rituximab (two 1000 mg infusions separated by two weeks) was evaluated in a 48-week, randomized trial with 22 patients with pemphigus vulgaris or pemphigus foliaceus [<a href="#rid43">43</a>]. The study population included both patients who had failed other therapies and patients who received rituximab as initial treatment. Most patients received systemic glucocorticoids in addition to rituximab, and adjuvant immunosuppressants (primarily <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>) were added for patients with incomplete responses to treatment.</p><p></p><p class="bulletIndent1">All 11 patients in the low-dose <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> group and 10 of 11 patients in the standard rheumatologic dosing group achieved complete remission. Although the trial did not find statistically significant differences in the primary endpoints (time to disease control, time to end of consolidation phase, time to partial remission, or time to complete remission) between the two groups, there was a nonstatistically significant trend towards greater risk for relapse among patients treated with low-dose rituximab than among patients given the rheumatologic dose regimen (64 versus 36 percent relapsed, respectively). In addition, patients in the low-dose rituximab group had a significantly higher cumulative dose of <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, and a statistically significant decline in enzyme-linked immunosorbent assay (ELISA) indices of desmoglein 1 and desmoglein 3 was evident only in the rheumatologic dose group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efgartigimod</strong> – An open-label, phase 2 study suggests intravenous efgartigimod, an engineered Fc fragment that reduced IgG levels through its affinity for the neonatal Fc receptor, may be a fast-acting treatment for mild to moderate pemphigus [<a href="#rid45">45</a>]. In the study, 28 of the 31 patients (90 percent) treated with efgartigimod alone or in combination with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> who were determined eligible for drug efficacy analysis achieved disease control, with a median time to disease control of 17 days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other therapies</strong> – Other examples include topical <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">pimecrolimus</a> [<a href="#rid46">46</a>], topical <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> [<a href="#rid47">47</a>], <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> with <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a>, gold [<a href="#rid48">48</a>], tetracyclines with or without <a class="drug drug_general" data-topicid="9696" href="/z/d/drug information/9696.html" rel="external">nicotinamide</a> [<a href="#rid49">49</a>], <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">chlorambucil</a>, mizoribine [<a href="#rid50">50</a>], and subcutaneous veltuzumab [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1">Although case reports have suggested benefit of the biologic tumor necrosis factor (TNF)-alpha inhibitors <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> and <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> in the treatment of pemphigus [<a href="#rid52">52-56</a>], a small, randomized trial that compared combination therapy with infliximab and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> with treatment with prednisone alone in 20 patients with pemphigus vulgaris found only nonstatistically significant trends towards better results with the addition of infliximab therapy [<a href="#rid57">57</a>]. The small size of the trial was a limiting factor; larger trials might clarify the effects of infliximab therapy.</p><p></p><p class="headingAnchor" id="H2258243375"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/132082.html" rel="external">"Society guideline links: Pemphigus"</a>.)</p><p class="headingAnchor" id="H13593245"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of initial treatment</strong> – Pemphigus vulgaris and pemphigus foliaceus are potentially life-threatening disorders. Initial treatment for these diseases consists of either combination therapy with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> and a systemic glucocorticoid or a systemic glucocorticoid given with or without an adjuvant immunosuppressant, such as <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (<a class="graphic graphic_algorithm graphicRef134326" href="/z/d/graphic/134326.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/15303.html" rel="external">"Initial management of pemphigus vulgaris and pemphigus foliaceus", section on 'Initial therapy'</a>.)</p><p></p><p class="bulletIndent1">Escalation of treatment is often the next step when patients fail to achieve disease control with the initial regimen (<a class="graphic graphic_algorithm graphicRef134326" href="/z/d/graphic/134326.html" rel="external">algorithm 1</a>). Escalation of treatment generally consists of increasing the dose of the systemic glucocorticoid, adding <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (if not already received), and/or adding or adjusting conventional immunosuppressive therapy. (See <a class="local">'Candidates'</a> above and  <a class="medical medical_review" href="/z/d/html/15303.html" rel="external">"Initial management of pemphigus vulgaris and pemphigus foliaceus", section on 'Failure to achieve disease control'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of treatments for refractory disease</strong> – Patients who do not respond sufficiently to initial treatment and escalation of treatment may benefit from other interventions, such as intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG), immunoadsorption, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and plasmapheresis. (See <a class="local">'Treatment options'</a> above.)</p><p></p><p class="bulletIndent1">Due to a lack of high-quality comparative trials, data are insufficient for definitive conclusions on the relative efficacies of therapies for refractory pemphigus. Factors such as patient tolerance for specific treatments and treatment availability influence treatment selection. (See <a class="local">'Treatment selection'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355:1772.</a></li><li><a class="nounderline abstract_t">Kasperkiewicz M, Shimanovich I, Meier M, et al. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol 2012; 166:154.</a></li><li><a class="nounderline abstract_t">Behzad M, Möbs C, Kneisel A, et al. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol 2012; 166:844.</a></li><li><a class="nounderline abstract_t">Shimanovich I, Nitschke M, Rose C, et al. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 2008; 158:382.</a></li><li><a class="nounderline abstract_t">Ahmed AR, Kaveri S, Spigelman Z. Long-Term Remissions in Recalcitrant Pemphigus Vulgaris. N Engl J Med 2015; 373:2693.</a></li><li><a class="nounderline abstract_t">Czernik A, Beutner EH, Bystryn JC. Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus. J Am Acad Dermatol 2008; 58:796.</a></li><li><a class="nounderline abstract_t">Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol 2020; 34:1900.</a></li><li><a class="nounderline abstract_t">Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: Recommendations of an international panel of experts. J Am Acad Dermatol 2020; 82:575.</a></li><li><a class="nounderline abstract_t">Amagai M, Ikeda S, Shimizu H, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009; 60:595.</a></li><li><a class="nounderline abstract_t">Herzog S, Schmidt E, Goebeler M, et al. Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins. Acta Derm Venereol 2004; 84:48.</a></li><li><a class="nounderline abstract_t">Seidling V, Hoffmann JH, Enk AH, Hadaschik EN. Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events. Acta Derm Venereol 2013; 93:346.</a></li><li><a class="nounderline abstract_t">Bystryn JC, Rudolph JL. IVI g TREATMENT OF PEMPHIGUS: how it works and how to use it. J Invest Dermatol 2005; 125:1093.</a></li><li><a class="nounderline abstract_t">Sami N, Qureshi A, Ruocco E, Ahmed AR. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol 2002; 138:1158.</a></li><li><a class="nounderline abstract_t">Green MG, Bystryn JC. Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris. Arch Dermatol 2008; 144:1621.</a></li><li><a class="nounderline abstract_t">Eming R, Hertl M. Immunoadsorption in pemphigus. Autoimmunity 2006; 39:609.</a></li><li><a class="nounderline abstract_t">Schmidt E, Klinker E, Opitz A, et al. Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 2003; 148:1222.</a></li><li><a class="nounderline abstract_t">Lüftl M, Stauber A, Mainka A, et al. Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol 2003; 149:598.</a></li><li><a class="nounderline abstract_t">Eming R, Rech J, Barth S, et al. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology 2006; 212:177.</a></li><li><a class="nounderline abstract_t">Günther C, Laske J, Frind A, et al. Successful therapy of pemphigus vulgaris with immunoadsorption using the TheraSorb adsorber. J Dtsch Dermatol Ges 2008; 6:661.</a></li><li><a class="nounderline abstract_t">Schmidt E, Zillikens D. Immunoadsorption in dermatology. Arch Dermatol Res 2010; 302:241.</a></li><li><a class="nounderline abstract_t">Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007; 57:622.</a></li><li><a class="nounderline abstract_t">Zhu LP, Cupps TR, Whalen G, Fauci AS. Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells. J Clin Invest 1987; 79:1082.</a></li><li><a class="nounderline abstract_t">Saha M, Powell AM, Bhogal B, et al. Pulsed intravenous cyclophosphamide and methylprednisolone therapy in refractory pemphigus. Br J Dermatol 2010; 162:790.</a></li><li><a class="nounderline abstract_t">Pasricha JS, Khaitan BK, Raman RS, Chandra M. Dexamethasone-cyclophosphamide pulse therapy for pemphigus. Int J Dermatol 1995; 34:875.</a></li><li><a class="nounderline abstract_t">Kaur S, Kanwar AJ. Dexamethasone-cyclophosphamide pulse therapy in pemphigus. Int J Dermatol 1990; 29:371.</a></li><li><a class="nounderline abstract_t">Sacchidanand S, Hiremath NC, Natraj HV, et al. Dexamethasone-cyclophosphamide pulse therapy for autoimmune-vesiculobullous disorders at Victoria hospital, Bangalore. Dermatol Online J 2003; 9:2.</a></li><li><a class="nounderline abstract_t">Rose E, Wever S, Zilliken D, et al. Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study. J Dtsch Dermatol Ges 2005; 3:200.</a></li><li><a class="nounderline abstract_t">Saxena S, Khurana A, Sardana K. Pulsed cyclophosphamide sans pulse steroids in recalcitrant pemphigus: An effective, economical but underutilized modality. Dermatol Ther 2022; 35:e15392.</a></li><li><a class="nounderline abstract_t">Sesso R, Monteiro M, Sato E, et al. A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis. Lupus 1994; 3:107.</a></li><li><a class="nounderline abstract_t">Cummins DL, Mimouni D, Anhalt GJ, Nousari CH. Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus. J Am Acad Dermatol 2003; 49:276.</a></li><li><a class="nounderline abstract_t">Nousari CH, Brodsky R, Anhalt GJ. Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris. J Am Acad Dermatol 2003; 49:148.</a></li><li><a class="nounderline abstract_t">Hayag MV, Cohen JA, Kerdel FA. Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris. J Am Acad Dermatol 2000; 43:1065.</a></li><li><a class="nounderline abstract_t">Ranugha PS, Kumari R, Kartha LB, et al. Therapeutic plasma exchange as a crisis option in severe pemphigus vulgaris. Indian J Dermatol Venereol Leprol 2012; 78:508.</a></li><li><a class="nounderline abstract_t">Cotterill JA, Barker DJ, Millard LG. Plasma exchange in the treatment of pemphigus vulgaris. Br J Dermatol 1978; 98:243.</a></li><li><a class="nounderline abstract_t">Roujeau JC, Andre C, Joneau Fabre M, et al. Plasma exchange in pemphigus. Uncontrolled study of ten patients. Arch Dermatol 1983; 119:215.</a></li><li><a class="nounderline abstract_t">Tan-Lim R, Bystryn JC. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. J Am Acad Dermatol 1990; 22:35.</a></li><li><a class="nounderline abstract_t">Søndergaard K, Carstens J, Jørgensen J, Zachariae H. The steroid-sparing effect of long-term plasmapheresis in pemphigus. Acta Derm Venereol 1995; 75:150.</a></li><li><a class="nounderline abstract_t">Turner MS, Sutton D, Sauder DN. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol 2000; 43:1058.</a></li><li><a class="nounderline abstract_t">Liu Y, Zhang B, Ma J, et al. Double-filtration plasmapheresis combined with immunosuppressive treatment for severe pemphigus: 10 years' experience of a single center in China. J Clin Apher 2021; 36:20.</a></li><li><a class="nounderline abstract_t">Guillaume JC, Roujeau JC, Morel P, et al. Controlled study of plasma exchange in pemphigus. Arch Dermatol 1988; 124:1659.</a></li><li><a class="nounderline abstract_t">Vinay K, Kanwar AJ, Mittal A, et al. Intralesional Rituximab in the Treatment of Refractory Oral Pemphigus Vulgaris. JAMA Dermatol 2015; 151:878.</a></li><li><a class="nounderline abstract_t">Horváth B, Huizinga J, Pas HH, et al. Low-dose rituximab is effective in pemphigus. Br J Dermatol 2012; 166:405.</a></li><li><a class="nounderline abstract_t">Kanwar AJ, Vinay K, Sawatkar GU, et al. Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study. Br J Dermatol 2014; 170:1341.</a></li><li><a class="nounderline abstract_t">Amber KT, Hertl M. An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab. J Eur Acad Dermatol Venereol 2015; 29:777.</a></li><li><a class="nounderline abstract_t">Goebeler M, Bata-Csörgő Z, De Simone C, et al. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial. Br J Dermatol 2022; 186:429.</a></li><li><a class="nounderline abstract_t">Iraji F, Asilian A, Siadat AH. Pimecrolimus 1% cream in the treatment of cutaneous lesions of pemphigus vulgaris: a double-blind, placebo-controlled clinical trial. J Drugs Dermatol 2010; 9:684.</a></li><li><a class="nounderline abstract_t">Cohen SN, Lim RP, Paul CJ, Abdullah A. Equal efficacy of topical tacrolimus and clobetasone butyrate in pemphigus foliaceus. Int J Dermatol 2006; 45:1379.</a></li><li><a class="nounderline abstract_t">Salomon D, Saurat JH. Oral gold therapy (Auranofin) in pemphigus vulgaris. Dermatologica 1986; 172:310.</a></li><li><a class="nounderline abstract_t">Chen S, Lu X, Zhou G. Mild pemphigus foliaceus responding to combination therapy with niacinamide and tetracycline. Int J Dermatol 2003; 42:981.</a></li><li><a class="nounderline abstract_t">Hashimoto T. Treatment strategies for pemphigus vulgaris in Japan. Expert Opin Pharmacother 2008; 9:1519.</a></li><li><a class="nounderline abstract_t">Ellebrecht CT, Choi EJ, Allman DM, et al. Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris. JAMA Dermatol 2014; 150:1331.</a></li><li><a class="nounderline abstract_t">Pardo J, Mercader P, Mahiques L, et al. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol 2005; 153:222.</a></li><li><a class="nounderline abstract_t">Jacobi A, Shuler G, Hertl M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol 2005; 153:448.</a></li><li><a class="nounderline abstract_t">Berookhim B, Fischer HD, Weinberg JM. Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept. Cutis 2004; 74:245.</a></li><li><a class="nounderline abstract_t">Lin MH, Hsu CK, Lee JY. Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch Dermatol 2005; 141:680.</a></li><li><a class="nounderline abstract_t">Shetty A, Marcum CB, Glass LF, Carter JD. Successful treatment of pemphigus vulgaris with etanercept in four patients. J Drugs Dermatol 2009; 8:940.</a></li><li><a class="nounderline abstract_t">Hall RP 3rd, Fairley J, Woodley D, et al. A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone. Br J Dermatol 2015; 172:760.</a></li></ol></div><div id="topicVersionRevision">Topic 15304 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17065638" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21910700" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22092243" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18070210" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26716930" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Long-Term Remissions in Recalcitrant Pemphigus Vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18423257" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32830877" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29438767" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Diagnosis and management of pemphigus: Recommendations of an international panel of experts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19293008" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A randomized double-blind trial of intravenous immunoglobulin for pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15040478" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23073990" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16354177" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : IVI g TREATMENT OF PEMPHIGUS: how it works and how to use it.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12224976" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19075146" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17101505" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Immunoadsorption in pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12828752" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14510995" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16484825" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18371053" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Successful therapy of pemphigus vulgaris with immunoadsorption using the TheraSorb adsorber.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20049466" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Immunoadsorption in dermatology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17583373" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3494044" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19922532" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pulsed intravenous cyclophosphamide and methylprednisolone therapy in refractory pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8647673" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Dexamethasone-cyclophosphamide pulse therapy for pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2361797" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Dexamethasone-cyclophosphamide pulse therapy in pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14996375" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Dexamethasone-cyclophosphamide pulse therapy for autoimmune-vesiculobullous disorders at Victoria hospital, Bangalore</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16372814" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35187764" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pulsed cyclophosphamide sans pulse steroids in recalcitrant pemphigus: An effective, economical but underutilized modality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7920609" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12894077" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12833031" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11100024" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22772632" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Therapeutic plasma exchange as a crisis option in severe pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/629881" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Plasma exchange in the treatment of pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6824359" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Plasma exchange in pemphigus. Uncontrolled study of ten patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2298963" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7604647" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The steroid-sparing effect of long-term plasmapheresis in pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11100023" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32812668" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Double-filtration plasmapheresis combined with immunosuppressive treatment for severe pemphigus: 10 years' experience of a single center in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3178248" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Controlled study of plasma exchange in pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25536513" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Intralesional Rituximab in the Treatment of Refractory Oral Pemphigus Vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21967609" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Low-dose rituximab is effective in pemphigus</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24640990" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25185723" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34608631" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20645531" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pimecrolimus 1% cream in the treatment of cutaneous lesions of pemphigus vulgaris: a double-blind, placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17076736" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Equal efficacy of topical tacrolimus and clobetasone butyrate in pemphigus foliaceus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3089850" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Oral gold therapy (Auranofin) in pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14636199" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mild pemphigus foliaceus responding to combination therapy with niacinamide and tetracycline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18518782" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Treatment strategies for pemphigus vulgaris in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25133328" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16029365" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Infliximab in the management of severe pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16086769" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15551718" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15967912" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19852124" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Successful treatment of pemphigus vulgaris with etanercept in four patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25123295" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
